The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
The Potential for microRNA Therapeutics and Clinical Research
Open accessAbstract
As FDA-approved small RNA drugs start to enter clinical medicine, ongoing studies for the microRNA (miRNA) class of small RNAs expand its preclinical and clinical research applications. A growing number of reports suggest a significant utility of miRNAs as biomarkers for pathogenic conditions, modulators of drug resistance, and/or as drugs for medical intervention in almost all human health conditions. The pleiotropic nature of this class of nonprotein-coding RNAs makes them particularly attractive drug targets for diseases with a multifactorial origin and no current effective treatments. As candidate miRNAs begin to proceed toward initiation and completion of potential phase 3 and 4 trials in the future, the landscape of both diagnostic and interventional medicine will arguably continue to evolve. In this mini-review, we discuss miRNA drug discovery development and their current status in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Guo, J., Jin, D., Wu, Y., Yang, L., Du, J., Gong, K., Chen, W., Dai, J., Miao, S., & Xi, S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.001 · Cited by 64
RetractedInitial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
MicroRNAs: Target Recognition and Regulatory Functions
Bartel, D. P. (2009) · Cell · doi:10.1016/j.cell.2009.01.002 · Cited by 20,068
Finishing the euchromatic sequence of the human genome
International Human Genome Sequencing Consortium (2004) · Nature · doi:10.1038/nature03001 · Cited by 4,971
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,854
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
The MicroRNA Spectrum in 12 Body Fluids
Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., How Huang, K., Jen Lee, M., Galas, D. J., & Wang, K. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.147405 · Cited by 2,477
Treatment of HCV Infection by Targeting MicroRNA
Janssen, H. L. A., Reesink, H. W., Lawitz, E. J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der Meer, A. J., Patick, A. K., Chen, A., Zhou, Y., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209026 · Cited by 2,204
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
The Landscape of long noncoding RNA classification
St. Laurent, G., Wahlestedt, C., & Kapranov, P. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.03.007 · Cited by 1,191
The majority of microRNAs detectable in serum and saliva is concentrated in exosomes
Gallo, A., Tandon, M., Alevizos, I., & Illei, G. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030679 · Cited by 1,060
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954 · cited 1×
“Modified micelle, liposome, nanoparticle, intranasal, and other delivery methods have all been tested for blood-brain barrier crossing and delivery with varying levels of success (Garg et al., 2015; Dong, 2018).”
BackgroundThe productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
van Zandwijk, N., Pavlakis, N., Kao, S. C., Linton, A., Boyer, M. J., Clarke, S., Huynh, Y., Chrzanowska, A., Fulham, M. J., Bailey, D. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30621-6 · Cited by 710
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Chen, Y., Gao, D.-Y., & Huang, L. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.05.009 · Cited by 672
Choi, C.-H. (2005) · Cancer Cell International · doi:10.1186/1475-2867-5-30 · Cited by 523
Preclinical and clinical development of siRNA-based therapeutics
Ozcan, G., Ozpolat, B., Coleman, R. L., Sood, A. K., & Lopez-Berestein, G. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.01.007 · Cited by 449
Tools for Sequence-Based miRNA Target Prediction: What to Choose?
Riffo-Campos, Á., Riquelme, I., & Brebi-Mieville, P. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121987 · Cited by 432
Induced Pluripotent Stem Cells and Their Use in Human Models of Disease and Development
Karagiannis, P., Takahashi, K., Saito, M., Yoshida, Y., Okita, K., Watanabe, A., Inoue, H., Yamashita, J. K., Todani, M., Nakagawa, M., et al. (2019) · Physiological Reviews · doi:10.1152/physrev.00039.2017 · Cited by 368
Cell-to-cell communication: microRNAs as hormones.
Bayraktar, R., Van Roosbroeck, K., & Calin, G. A. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12144 · Cited by 361
Kim, B., & Feldman, E. L. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.3 · Cited by 355
Patisiran, an RNAi Therapeutic for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis
Kristen, A. V., Ajroud-Driss, S., Conceição, I., Gorevic, P., Kyriakides, T., & Obici, L. (2019) · Neurodegenerative Disease Management · doi:10.2217/nmt-2018-0033 · Cited by 268
Buschmann, D., Kirchner, B., Hermann, S., Märte, M., Wurmser, C., Brandes, F., Kotschote, S., Bonin, M., Steinlein, O. K., Pfaffl, M. W., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1481321 · Cited by 258
Mercatelli, N., Coppola, V., Bonci, D., Miele, F., Costantini, A., Guadagnoli, M., Bonanno, E., Muto, G., Frajese, G. V., De Maria, R., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0004029 · Cited by 250
Reid, G., Kao, S. C., Pavlakis, N., Brahmbhatt, H., MacDiarmid, J., Clarke, S., Boyer, M., & van Zandwijk, N. (2016) · Epigenomics · doi:10.2217/epi-2016-0035 · Cited by 242
Combination therapy to checkmate Glioblastoma: clinical challenges and advances
Ghosh, D., Nandi, S., & Bhattacharjee, S. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0211-8 · Cited by 227
miR-155 in cancer drug resistance and as target for miRNA-based therapeutics
Bayraktar, R., & Van Roosbroeck, K. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9724-7 · Cited by 216
Alterations of Serum Levels of BDNF-Related miRNAs in Patients with Depression
Li, Y.-J., Xu, M., Gao, Z.-H., Wang, Y.-Q., Yue, Z., Zhang, Y.-X., Li, X.-X., Zhang, C., Xie, S.-Y., & Wang, P.-Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063648 · Cited by 202
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
Van Roosbroeck, K., Fanini, F., Setoyama, T., Ivan, C., Rodriguez-Aguayo, C., Fuentes-Mattei, E., Xiao, L., Vannini, I., Redis, R. S., D'Abundo, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1025 · Cited by 178
Development of biomarkers for Huntington's disease
Weir, D. W., Sturrock, A., & Leavitt, B. R. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70070-9 · Cited by 161
Circulating microRNAs are promising novel biomarkers for drug-resistant epilepsy
Wang, J., Tan, L., Tan, L., Tian, Y., Ma, J., Tan, C., Wang, H.-F., Liu, Y., Tan, M., Jiang, T., et al. (2015) · Scientific Reports · doi:10.1038/srep10201 · Cited by 157
Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells
Kanlikilicer, P., Rashed, M. H., Bayraktar, R., Mitra, R., Ivan, C., Aslan, B., Zhang, X., Filant, J., da Silva, A. M., Rodriguez‐Aguayo, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0714 · Cited by 136
Circulating MicroRNAs are Promising Novel Biomarkers of Acute Myocardial Infarction
Wang, R., Li, N., Zhang, Y., Ran, Y., & Pu, J. (2011) · Internal Medicine · doi:10.2169/internalmedicine.50.5129 · Cited by 135
Functional miRNAs in breast cancer drug resistance
Hu, W., Tan, C., He, Y., Zhang, G., Xu, Y., & Tang, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s152462 · Cited by 130
Tsuji, O., Sugai, K., Yamaguchi, R., Tashiro, S., Nagoshi, N., Kohyama, J., Iida, T., Ohkubo, T., Itakura, G., Isoda, M., et al. (2018) · Stem Cells · doi:10.1002/stem.2926 · Cited by 129
Sun, X., Lu, J. Z., Zhang, L., Song, H., Zhao, L., Fan, H., Zhong, A., Niu, W., Guo, Z.-M., Dai, Y., et al. (2014) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2014.08.018 · Cited by 102
Garg, T., Bhandari, S., Rath, G., & Goyal, A. K. (2015) · Journal of drug targeting · doi:10.3109/1061186x.2015.1029930 · Cited by 86
Circulating MicroRNAs: A Next-Generation Clinical Biomarker for Digestive System Cancers
Kawaguchi, T., Komatsu, S., Ichikawa, D., Tsujiura, M., Takeshita, H., Hirajima, S., Miyamae, M., Okajima, W., Ohashi, T., Imamura, T., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091459 · Cited by 79
Wagh, V., Urhekar, A. D., & Modi, D. N. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.10.007 · Cited by 77
Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
Yang, J. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1567326 · Cited by 76
McCall, R., Miles, M. H., Lascuna, P., Burney, B., Patel, Z., Sidoran, K. J., Sittaramane, V. K., Kocerha, J., Grossie, D. A., Sessler, J. L., et al. (2017) · Chemical Science · doi:10.1039/c7sc02153d · Cited by 73
Self-citationComputational analysis of noncoding RNAs
Stefan Washietl, A., Will, S., Hendrix, D. A., Goff, L. A., Rinn, J. L., Berger, B., & Kellis, M. (2012) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1134 · Cited by 65
Rashed, M. H., Kanlikilicer, P., Rodriguez‐Aguayo, C., Pichler, M., Bayraktar, R., Bayraktar, E., Ivan, C., Filant, J., da Silva, A. M., Aslan, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15525 · Cited by 63
Kocerha, J., Kouri, N., Baker, M. C., Finch, N. A., DeJesus‐Hernandez, M., Gonzalez, J., Chidamparam, K., Josephs, K. A., Boeve, B. F., Graff‐Radford, N. R., et al. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-527 · Cited by 57
Self-citationThinking small: towards microRNA-based therapeutics for anxiety disorders
Scott, K. A., Hoban, A. E., Clarke, G., Moloney, G. M., Dinan, T. G., & Cryan, J. F. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.997873 · Cited by 52
MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer
Biswas, S. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666181120121830 · Cited by 49
Paškevičiūtė, M., & Petrikaitė, V. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0584-7 · Cited by 48
Current chemotherapy strategies in malignant pleural mesothelioma
de Gooijer, C. J., Baas, P., & Burgers, J. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.04.10 · Cited by 47
Circulating microRNAs: promising candidates serving as novel biomarkers of acute hepatitis
Elfimova, N., Schlattjan, M., Sowa, J., Dienes, H. P., Canbay, A. E., & Odenthal, M. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00476 · Cited by 44
Xie, Y., Shao, Y., Deng, X., Wang, M., & Chen, Y. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00602 · Cited by 38
Recchioni, R., Marcheselli, F., Olivieri, F., Ricci, S., Procopio, A. D., & Antonicelli, R. (2013) · Biomarkers · doi:10.3109/1354750x.2013.833294 · Cited by 35
Niacin induces miR-502-3p expression which impairs insulin sensitivity in human adipocytes
Montastier, É., Beuzelin, D., Martins, F., Mir, L., Marqués, M.-A., Thalamas, C., Iacovoni, J. S., Langin, D., & Viguerie, N. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0260-5 · Cited by 31
Evaluating the Phase II drugs currently under investigation for diabetic neuropathy
Adeghate, E. A., Fehér, E., & Kalász, H. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.954033 · Cited by 28
Lekprasert, P., Mayhew, M. B., & Ohler, U. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020622 · Cited by 27
Gupta, S. N., Singhal, N. K., Ganesh, S., & Sandhir, R. (2018) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527317666181114163515 · Cited by 16
Cited by
Drug delivery systems for RNA therapeutics
Paunovska, K., Loughrey, D., & Dahlman, J. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-021-00439-4 · Cited by 1,349
Goodall, G. J., & Wickramasinghe, V. O. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00306-0 · Cited by 1,066
Ratti, M., Lampis, A., Ghidini, M., Salati, M., Mirchev, M. B., Valeri, N., & Hahne, J. C. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00717-x · Cited by 606
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Lu, Y., Chan, Y.-T., Tan, H.-Y., Li, S., Wang, N., & Feng, Y. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01197-3 · Cited by 499
Metadata
- Authors
- Hanna, J., Hossain, G. S., & Kocerha, J.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2019-05-16
- Volume
- 10
- Pages
- 478-478
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2946714259
- Cited by
- 726
- References
- 56
- FWCI
- 31.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.